Renaissance Capital logo

Genmab Priced, Nasdaq: GMAB

Developing novel antibodies for cancer and other diseases.

Industry: Health Care

Latest Trade: $18.18 0.00 (0.0%)

First Day Return: +2.4%

Return from IPO: +2.4%

Industry: Health Care

We are an international biotechnology company specializing in antibody therapeutics for the treatment of cancer and other diseases. Our core purpose is to improve the lives of patients by creating and developing innovative antibody products. Our vision is to transform cancer treatment by launching our own proprietary product by 2025 and advancing our pipeline of differentiated and well-tolerated antibodies. We are building and expanding our late-stage development and commercial capabilities to allow us to bring our proprietary products to market in the future. Today, we have a well-diversified portfolio of products, product candidates and technologies. Our portfolio includes two marketed partnered products, daratumumab, marketed as DARZALEX for the treatment of certain MM indications, and ofatumumab, marketed as Arzerra for the treatment of certain CLL indications, in addition to a broad pipeline of differentiated product candidates. Our pipeline includes five proprietary product candidates in clinical development and approximately 20 proprietary and partnered pre-clinical programs, including two proprietary product candidates for which we have submitted or intend to submit an IND to the FDA and/or a CTA to the EMA in 2019.
more less
IPO News for Genmab
more
IPO Data
IPO File Date 05/28/2019
Offer Price $17.75
Price Range $18.11 - $18.11
Offer Shares (mm) 28.5
Deal Size ($mm) $506
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 07/17/2019
Offer Price $17.75
Price Range $18.11 - $18.11
Offer Shares (mm) 28.5
Deal Size ($mm) $506
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
Underwriters
more
Company Data
Headquarters Copenhagen, Denmark
Founded 1998
Employees 419
Website www.genmab.com